These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16918261)

  • 1. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
    Steinfeld SD; Youinou P
    Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
    Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
    Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
    Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
    Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.
    Goldenberg DM; Stein R; Leonard JP; Steinfeld SD; Dörner T; Burmester GR
    Arthritis Rheum; 2006 Jul; 54(7):2344; author reply 2344-5. PubMed ID: 16802381
    [No Abstract]   [Full Text] [Related]  

  • 5. Epratuzumab for the treatment of systemic lupus erythematosus.
    Geh D; Gordon C
    Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of systemic lupus erythematosus with epratuzumab.
    Traczewski P; Rudnicka L
    Br J Clin Pharmacol; 2011 Feb; 71(2):175-82. PubMed ID: 21219397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epratuzumab for systemic lupus erythematosus.
    Wallace DJ; Goldenberg DM
    Lupus; 2013 Apr; 22(4):400-5. PubMed ID: 23553783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again.
    Eisenberg R
    Arthritis Res Ther; 2006; 8(3):108. PubMed ID: 16732895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-B cell antibody therapies for inflammatory rheumatic diseases.
    Faurschou M; Jayne DR
    Annu Rev Med; 2014; 65():263-78. PubMed ID: 24160940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
    Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
    Dörner T; Shock A; Goldenberg DM; Lipsky PE
    Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gnawing at Metchnikoff's paradigm.
    Taylor RP
    Blood; 2013 Oct; 122(17):2922-4. PubMed ID: 24159161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.
    Rao V; Gordon C
    Immunotherapy; 2014; 6(11):1165-75. PubMed ID: 25496332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of B cell-targeted therapies in Sjögren's syndrome.
    Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
    Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD22 and autoimmune disease.
    Dörner T; Shock A; Smith KG
    Int Rev Immunol; 2012 Oct; 31(5):363-78. PubMed ID: 23083346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
    Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
    Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
    Rossi EA; Chang CH; Goldenberg DM
    PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.
    Dörner T; Kaufmann J; Wegener WA; Teoh N; Goldenberg DM; Burmester GR
    Arthritis Res Ther; 2006; 8(3):R74. PubMed ID: 16630358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epratuzumab in the therapy of oncological and immunological diseases.
    Goldenberg DM
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1341-53. PubMed ID: 17069520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.